[ Back to EurekAlert! ]

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology

Radioactive Iodine-Refractory Thyroid Cancer: Sorafenib, a New Treatment Option

Loading video...

Caption: L. Licitra shares her comments about randomized, phase III DECISION trial that studied sorafenib, an orally active inhibitor of VEGFR1-3 and Raf kinases, vs. placebo in patients with progressive locally advanced/metastatic radioactive iodine-refractory differentiated thyroid cancer. The standard treatment in this situation is a classical chemotherapy and now targeted therapy with sorafenib shows improved progression-free survival with tolerability consistent with known sorafenib safety profile. http://www.esmo.org

Credit: European Society for Medical Oncology

Usage Restrictions: None


[ Back to EurekAlert! ]